Affinage

ABHD12

Lysophosphatidylserine lipase ABHD12 · UniProt Q8N2K0

Length
398 aa
Mass
45.1 kDa
Annotated
2026-06-09
40 papers in source corpus 17 papers cited in narrative 16 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ABHD12 is an integral endoplasmic reticulum membrane serine hydrolase that degrades bioactive lysophospholipids and endocannabinoids, thereby controlling neuroinflammation and the lipid signals that drive PHARC neuropathology (PMID:20797687, PMID:23297193, PMID:30237167). Catalysis depends on a serine hydrolase triad (S246-D333-H372), whose mutation abolishes both enzymatic activity and active-site probe labeling (PMID:22969151). Although first characterized as a 2-arachidonoylglycerol (2-AG) hydrolase that contributes to brain endocannabinoid turnover (PMID:20797687, PMID:21418147, PMID:22969151), its principal physiological role is as a lysophosphatidylserine (lyso-PS) lipase with strong preference for very-long-chain substrates, a selectivity reinforced by its glycosylation-dependent activity and ER localization (PMID:23297193, PMID:30237167); it additionally hydrolyzes oxidized phosphatidylserine and lysophosphatidylinositol (PMID:30643283, PMID:30720278). ABHD12 operates within an ABHD16A-ABHD12 axis—ABHD16A generating lyso-PS and ABHD12 degrading it—that dynamically sets lyso-PS tone, most prominently in the cerebellum, and coordinates with the Lands-cycle remodeler LPCAT3 to balance lyso-PS and arachidonoyl-PS pools (PMID:25580854, PMID:32364701, PMID:32462874). Loss of ABHD12 causes accumulation of proinflammatory TLR2-activating lyso-PS lipids, microglial activation, and progressive auditory and motor defects modeling PHARC, and ABHD12 was identified as the gene mutated in PHARC disease (PMID:20797687, PMID:23297193). Functionally, ABHD12 restrains innate immune and phagocyte responses: its activity suppresses inflammatory cytokine production, modulates ferroptotic sensitivity, regulates phagocyte-mediated axon elimination downstream of SARM1, and in microglia is post-translationally controlled to govern 2-AG-mediated immunosuppression via CB2R and PGE2 pathways (PMID:30420694, PMID:32195565, PMID:40496808, PMID:38979309, PMID:41983263).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2010 High

    Establishing the disease link and an enzymatic activity converted an uncharacterized gene into a defined inborn error of lipid metabolism, framing PHARC as a hydrolase deficiency.

    Evidence Human genetics mutation identification combined with biochemical 2-AG hydrolase data

    PMID:20797687

    Open questions at the time
    • Did not establish which lipid substrate is pathophysiologically relevant
    • No subcellular localization or structural detail
  2. 2012 High

    Defining the catalytic triad and confirming monoacylglycerol lipase activity pinned the molecular basis of catalysis and licensed activity-based profiling of the enzyme.

    Evidence Recombinant human ABHD12 fluorescent glycerol assay, catalytic-triad mutagenesis, and TAMRA-FP activity-based profiling

    PMID:22969151

    Open questions at the time
    • Did not address whether MAG is the primary physiological substrate
    • No in vivo substrate validation
  3. 2013 High

    Identifying lyso-PS as a principal brain substrate redefined ABHD12's physiological role and linked its loss mechanistically to TLR2-driven microglial activation and PHARC-like phenotypes.

    Evidence Untargeted metabolomics of ABHD12-/- mouse brain, recombinant lyso-PS lipase assay, and knockout behavioral phenotyping; ABPP in patient lymphoblastoid cells

    PMID:23297193 PMID:24027063

    Open questions at the time
    • Did not identify the lyso-PS-generating enzyme
    • Chain-length basis of substrate accumulation not yet explained
  4. 2015 High

    Placing ABHD12 opposite ABHD16A defined a metabolic axis that sets lyso-PS levels and bidirectionally tunes innate immune output.

    Evidence ABPP, pharmacology, Abhd12-/- and Abhd16a-/- mice, lipidomics, and macrophage cytokine assays

    PMID:25580854

    Open questions at the time
    • Direct physical interaction between the two enzymes not addressed
    • Tissue-specific contributions not resolved
  5. 2016 High

    Disease-mutation enzymology plus a rescuable animal model proved that loss of catalytic activity is the cause of the multi-system PHARC phenotype.

    Evidence MAG lipase assays of disease mutants in HEK293, zebrafish morpholino knockdown, and wild-type versus mutant mRNA rescue

    PMID:27890673

    Open questions at the time
    • Mechanism connecting lipid changes to myelination and sensory defects not defined
    • Morpholino off-target effects inherent to method
  6. 2018 High

    Defining glycosylation dependence, very-long-chain substrate preference, and ER localization explained the specific lipid species that accumulate on enzyme loss.

    Evidence Substrate library profiling, organelle fractionation, immunofluorescence, and validation in WT and knockout brain membranes; selective inhibitor DO264 in vivo and LCMV infection model

    PMID:30237167 PMID:30420694

    Open questions at the time
    • No structural model of substrate selectivity
    • Receptors mediating in vivo lyso-PS immune effects beyond TLR2 not fully defined
  7. 2019 High

    Expanding the substrate scope to oxidized PS and lyso-PI tied ABHD12 to oxidative-stress lipid signaling and innate immune suppression.

    Evidence ROS-driven chemical-genetic screen with knockout validation; ABPP-guided inhibitor and substrate assays with cytokine readout in THP-1 macrophages

    PMID:30643283 PMID:30720278

    Open questions at the time
    • Relative physiological contribution of each substrate class unresolved
    • Lyso-PI specificity not independently replicated at same rigor
  8. 2020 High

    Genetic epistasis and regional and cell-type mapping placed ABHD12 within a Lands-cycle remodeling network and localized its lyso-PS axis activity to the cerebellum, while linking it to ferroptosis.

    Evidence ABHD12-/- x LPCAT3-/- double-knockout lipidomics and phenotyping; cerebellar immunohistochemistry with knockout controls; ferroptosis assays in HT1080 cells

    PMID:32195565 PMID:32364701 PMID:32462874

    Open questions at the time
    • Causal bioactive lyso-PS species driving PHARC not pinpointed
    • Ferroptosis mechanism characterized in a single lab
  9. 2024 Medium

    Gain-of-function rescue positioned ABHD12-mediated PS metabolism downstream of SARM1 in regulating phagocyte-driven axon degeneration.

    Evidence Transgenic neuronal ABHD12 overexpression in NMNAT2 hypomorphic sarmopathy mice with motor, axon morphology, and macrophage activation readouts

    PMID:38979309 PMID:40496808

    Open questions at the time
    • Direct lipid mediator linking ABHD12 to axon protection not defined
    • Single lab study
  10. 2026 Medium

    Discovering post-translational control of ABHD12 activity in microglia and dissecting CB2R and PGE2 branches clarified how its 2-AG hydrolysis governs context-dependent immune signaling.

    Evidence ABPP with tailored probe LEI-612, microglial-state lipidomics, DO264 inhibition, CB2R antagonism, and cytokine measurements

    PMID:41983263

    Open questions at the time
    • Identity of the post-translational modification regulating activity unknown
    • Single lab study

Open questions

Synthesis pass · forward-looking unresolved questions
  • How distinct substrate pools (lyso-PS, ox-PS, 2-AG, lyso-PI) are differentially channeled to specific receptors and pathologies, and the structural basis of very-long-chain selectivity, remain unresolved.
  • No experimental structure of ABHD12
  • Mechanism partitioning substrate use across cell types and disease contexts undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016787 hydrolase activity 6 GO:0008289 lipid binding 2 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0005783 endoplasmic reticulum 2
Pathway
R-HSA-168256 Immune System 4 R-HSA-1430728 Metabolism 3 R-HSA-162582 Signal Transduction 2 R-HSA-5357801 Programmed Cell Death 2

Evidence

Reading pass · 16 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 ABHD12 was identified as the gene mutated in PHARC disease, and the encoded enzyme hydrolyzes 2-arachidonoylglycerol (2-AG), the main endocannabinoid lipid transmitter acting on cannabinoid receptors CB1 and CB2, establishing PHARC as an inborn error of endocannabinoid metabolism. Human genetics (mutation identification) combined with published biochemical data on 2-AG hydrolase activity American journal of human genetics High 20797687
2011 ABHD12 is highly expressed in microglia and accounts for approximately 9% of total brain 2-AG hydrolase activity, positioning it as a serine hydrolase that degrades the endocannabinoid 2-AG in the brain. Activity-based biochemical assays of brain 2-AG hydrolase activity combined with expression profiling Acta physiologica (Oxford, England) Medium 21418147
2012 Human ABHD12 is a genuine monoacylglycerol (MAG) lipase with preference for the 1(3)- and 2-isomers of arachidonoylglycerol; the catalytic triad residues S246-D333-H372 are essential for enzymatic activity and for labeling by the active-site serine-directed probe TAMRA-FP, as shown by site-directed mutagenesis abolishing both activity and probe labeling. Fluorescent glycerol assay with recombinant human ABHD12; site-directed mutagenesis of catalytic triad; activity-based protein profiling with TAMRA-FP Journal of lipid research High 22969151
2013 ABHD12 is a principal lysophosphatidylserine (LPS) lipase in the mammalian brain; recombinant ABHD12 exhibits robust LPS lipase activity, ABHD12-/- mice show massive accumulation of very-long-chain LPS lipids that are TLR2 activators, and loss of ABHD12 leads to microglial activation followed by auditory and motor defects resembling PHARC. Untargeted metabolomics of ABHD12-/- mouse brain; recombinant protein LPS lipase activity assay; genetic mouse model with behavioral phenotyping Proceedings of the National Academy of Sciences of the United States of America High 23297193
2013 Loss-of-function mutations in ABHD12 result in absence of ABHD12 hydrolase activity as measured by activity-based protein profiling (ABPP) of serine hydrolases in patient-derived lymphoblastoid cell lines, and heterozygous deletion causes ~50% reduction in ABHD12 activity, confirming that mutations directly impair enzyme function. Activity-based protein profiling (ABPP) of serine hydrolases in patient-derived lymphoblastoid cell lines; quantitative RT-PCR Human mutation Medium 24027063
2015 ABHD16A functions as a phosphatidylserine (PS) lipase that generates lyso-PS in mammalian systems, and ABHD12 degrades lyso-PS; these two enzymes form an ABHD16A-ABHD12 axis that dynamically regulates lyso-PS metabolism in vivo. In mouse macrophages, disruption of ABHD12 increases lyso-PS levels and enhances LPS-induced cytokine production, while ABHD16A disruption has the opposite effect. Activity-based protein profiling; pharmacological inhibition; genetic knockouts (Abhd12-/- and Abhd16a-/- mice); lipidomics; cytokine measurements in macrophages Nature chemical biology High 25580854
2016 ABHD12 mutations (T253R, T202I, R352*) abolish monoacylglycerol lipase activity in transfected HEK293 cells; knockdown of zebrafish abhd12 causes myelination defects, progressive ataxia, motor impairment, retinal architecture disruption, lens clarification inhibition, and reduced mechanosensory hair cells — phenotypes rescued by wild-type human ABHD12 mRNA but not by mutation-harboring mRNAs. MAG lipase activity assay in transfected HEK293 cells; zebrafish morpholino knockdown; mRNA rescue experiments with wild-type vs. mutant ABHD12 Neurobiology of disease High 27890673
2018 ABHD12 requires glycosylation for optimal enzymatic activity and has a strong preference for very-long-chain lipid substrates; ABHD12 is enriched on the endoplasmic reticulum membrane, as shown by cellular organelle fractionation and immunofluorescence, explaining the accumulation of very-long-chain LPS lipids in ABHD12 knockout mouse brains. Biochemical substrate profiling with a lipid library of varying chain lengths; cellular organelle fractionation; immunofluorescence; validation in brain membrane lysates from WT and ABHD12-/- mice The Journal of biological chemistry High 30237167
2018 Pharmacological inhibition of ABHD12 with the selective inhibitor DO264 elevates lyso-PS in mouse brain and primary human macrophages, and both DO264-treated and ABHD12-/- mice display heightened immunological responses to LCMV infection with severe lung pathology and elevated proinflammatory chemokines, demonstrating that ABHD12 regulates immunostimulatory lyso-PS lipid pathways in vivo. Selective small-molecule inhibitor (DO264) in vivo; ABHD12-/- mice; viral infection model (LCMV); lipidomics; cytokine/chemokine measurements Nature chemical biology High 30420694
2019 ABHD12 hydrolyzes oxidized phosphatidylserine (ox-PS), a proapoptotic 'eat me' signal generated under oxidative stress; this activity was identified via a chemical-genetic screen and validated in primary peritoneal macrophages and brains from Abhd12-/- mice under inflammatory stress. Chemical-genetic screen using a ROS-generating small molecule; lipidomics; validation in primary macrophages and Abhd12-/- mouse brain under inflammatory conditions Nature chemical biology High 30643283
2019 ABHD12 acts on both lysophosphatidylserine (lyso-PS) and lysophosphatidylinositol (lyso-PI) as substrates; the selective inhibitor DO264 augments inflammatory cytokine production from human THP-1 macrophage cells, confirming that ABHD12 enzymatic activity suppresses innate immune responses. Activity-based protein profiling (ABPP)-guided inhibitor development; substrate assays with lyso-PS and lyso-PI; cytokine production assay in human THP-1 macrophages Journal of medicinal chemistry Medium 30720278
2020 Genetic deletion of the lysophospholipid acyltransferase LPCAT3 blocks accumulation of brain arachidonoyl (C20:4) PS in ABHD12-/- mice while producing hyper-increases in lyso-PS, demonstrating that ABHD12 and LPCAT3 coordinately regulate lyso-PS and C20:4 PS content in the CNS through a Lands cycle-like remodeling pathway; lyso-PS lipids are identified as likely bioactive metabolites contributing to PHARC neuropathologies. Double-knockout mouse model (ABHD12-/- × LPCAT3-/-); brain lipidomics; auditory function testing; microgliosis assessment Biochemistry High 32364701
2020 Pharmacological inhibition or genetic disruption of ABHD12 potentiates ferroptosis in HT1080 cancer cells induced by the GPX4 inhibitor RSL3; ABHD12-inactivated cells show elevated lyso-PS, increased arachidonate (C20:4)-containing PS, and elevated 2-AG, identifying ABHD12 as a regulator of ferroptotic sensitivity through oxidation-sensitive lipid mediators. Small-molecule screen with serine hydrolase inhibitors; ABHD12 genetic disruption; metabolomics in RSL3-treated cells; ferroptosis cell death assays ACS chemical biology Medium 32195565
2020 Using immunohistochemistry with ABHD16A and ABHD12 knockout mice as controls, ABHD12 and ABHD16A are shown to localize to distinct regions and cell types in the cerebellum; cerebellar lyso-PS levels are most affected by deletion of ABHD12 (increased) or ABHD16A (decreased), establishing the cerebellum as the brain region where the ABHD16A-ABHD12 lyso-PS axis is most active. Immunohistochemistry with knockout mouse controls; subcellular organelle fractionation; mass spectrometry-based quantitative lipidomics of brain regions Biochemistry Medium 32462874
2024 Neuronal overexpression of ABHD12 (a PS lipase) suppresses macrophage activation, preserves motor axon integrity, and rescues motor function in a chronic SARM1-activation (sarmopathy) mouse model, demonstrating that ABHD12-mediated PS metabolism regulates phagocyte-mediated axon elimination downstream of SARM1 activation. Transgenic neuronal overexpression of ABHD12 in NMNAT2 hypomorphic mouse model; motor function behavioral assays; axon morphology analysis; macrophage activation assessment iScience Medium 38979309 40496808
2026 In microglia, ABHD12 activity is uncoupled from transcript and protein expression levels (indicative of post-translational regulation); cellular ABHD12 activity inversely correlates with 2-AG levels, and pharmacological inhibition of ABHD12 elevates 2-AG, reduces arachidonic acid (AA), and modulates cytokine release through dual mechanisms: CB2R-dependent suppression of TNF-α and PGE2-dependent regulation of IL-6. Activity-based protein profiling (ABPP) with tailored probe LEI-612; targeted lipidomics across microglial states; pharmacological inhibition with DO264; CB2R antagonism; cytokine measurements ACS chemical neuroscience Medium 41983263

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta physiologica (Oxford, England) 221 21418147
2010 Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. American journal of human genetics 171 20797687
2012 Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). Journal of lipid research 150 22969151
2013 ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proceedings of the National Academy of Sciences of the United States of America 143 23297193
2015 Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nature chemical biology 127 25580854
2012 Targeted next-generation sequencing identifies a homozygous nonsense mutation in ABHD12, the gene underlying PHARC, in a family clinically diagnosed with Usher syndrome type 3. Orphanet journal of rare diseases 64 22938382
2019 A chemical-genetic screen identifies ABHD12 as an oxidized-phosphatidylserine lipase. Nature chemical biology 62 30643283
2018 Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo. Nature chemical biology 55 30420694
2014 Exome sequencing extends the phenotypic spectrum for ABHD12 mutations: from syndromic to nonsyndromic retinal degeneration. Ophthalmology 45 24697911
2013 Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects. Human mutation 43 24027063
2020 Blockade of the Lysophosphatidylserine Lipase ABHD12 Potentiates Ferroptosis in Cancer Cells. ACS chemical biology 42 32195565
2019 Discovery and Optimization of Selective and in Vivo Active Inhibitors of the Lysophosphatidylserine Lipase α/β-Hydrolase Domain-Containing 12 (ABHD12). Journal of medicinal chemistry 36 30720278
2016 Functional validation of ABHD12 mutations in the neurodegenerative disease PHARC. Neurobiology of disease 35 27890673
2018 Biochemical characterization of the PHARC-associated serine hydrolase ABHD12 reveals its preference for very-long-chain lipids. The Journal of biological chemistry 34 30237167
2020 Mapping the Neuroanatomy of ABHD16A, ABHD12, and Lysophosphatidylserines Provides New Insights into the Pathophysiology of the Human Neurological Disorder PHARC. Biochemistry 27 32462874
2015 Novel ABHD12 mutations in PHARC patients: the differential diagnosis of deaf-blindness. The Annals of otology, rhinology, and laryngology 27 25743180
2014 Discovery of triterpenoids as reversible inhibitors of α/β-hydrolase domain containing 12 (ABHD12). PloS one 26 24879289
2020 ABHD12 and LPCAT3 Interplay Regulates a Lyso-phosphatidylserine-C20:4 Phosphatidylserine Lipid Network Implicated in Neurological Disease. Biochemistry 25 32364701
2017 A complex homozygous mutation in ABHD12 responsible for PHARC syndrome discovered with NGS and review of the literature. Journal of the peripheral nervous system : JPNS 24 28448692
2018 Phenotypical features of two patients diagnosed with PHARC syndrome and carriers of a new homozygous mutation in the ABHD12 gene. Journal of the neurological sciences 20 29571850
2018 Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. Amino acids 18 30564946
2020 Genotype-phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome. Journal of the peripheral nervous system : JPNS 16 32077159
2020 Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. Biochimica et biophysica acta. Molecular and cell biology of lipids 16 32829065
2019 A novel ABHD12 nonsense variant in Usher syndrome type 3 family with genotype-phenotype spectrum review. Gene 16 30974196
2021 The Phenotypic Spectrum of Patients with PHARC Syndrome Due to Variants in ABHD12: An Ophthalmic Perspective. Genes 14 34573385
2020 ABHD12 Knockdown Suppresses Breast Cancer Cell Proliferation, Migration and Invasion. Anticancer research 13 32366405
2024 Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung. Cancer immunology research 11 38215051
2023 Genetic insights into PHARC syndrome: identification of a novel frameshift mutation in ABHD12. BMC medical genomics 7 37803361
2016 A Sensitive and Versatile Fluorescent Activity Assay for ABHD12. Methods in molecular biology (Clifton, N.J.) 4 27245904
2025 Suppressing phagocyte activation by overexpressing the phosphatidylserine lipase ABHD12 preserves sarmopathic nerves. iScience 3 40496808
2023 Probing the Interactions of Thiazole Abietane Inhibitors with the Human Serine Hydrolases ABHD16A and ABHD12. ACS medicinal chemistry letters 3 37849541
2023 ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma. iScience 3 38053637
2024 Suppressing phagocyte activation by overexpressing the phosphatidylserine lipase ABHD12 preserves sarmopathic nerves. bioRxiv : the preprint server for biology 2 38979309
2024 Genotype-phenotype spectrum and correlation of PHARC Syndrome due to pathogenic ABHD12 variants. BMC medical genomics 2 39123271
2025 A Novel Compound Heterozygous Variant in the ABHD12 Gene Cause PHARC Syndrome in a Chinese Family: The Proband Presenting New Genotype and Phenotype. Molecular genetics & genomic medicine 1 39910854
2026 Stimulus-Driven Remodeling of Microglial Endocannabinoid Metabolism Illuminates ABHD12 Function in Immunity. ACS chemical neuroscience 0 41983263
2026 Multi-Omics Characterization of ABHD12 Across Pan-Cancer and Validation of Its Role in Promoting Proliferation and Metastasis in Breast Cancer. Breast cancer (Dove Medical Press) 0 42083571
2026 Potentially functional variants of CYP2A6 and ABHD12 in the arachidonic acid metabolism pathway genes predict the survival of HBV-related hepatocellular carcinoma patients. BMC cancer 0 42174523
2025 Generation of a human iPSC line (UCLi025-A) from a patient with PHARC syndrome harbouring biallelic variants in ABHD12. Stem cell research 0 39826350
2025 Case Report: novel GUCA1B and ABHD12 mutations in retinitis pigmentosa sine pigmento: expanding the genotypic spectrum through multimodal phenotyping. Frontiers in medicine 0 41189896

Missed literature

Know a paper Affinage missed for ABHD12? Flag it for the maintainers and the community.

No submissions yet.